Novo Nordisk moves to Delhi HC’s division bench to block Dr Reddy’s Semaglutide exports

Danish pharmaceutical manufacturer Novo Nordisk, Dr. It moved the division bench of the Delhi High Court to restrain Reddy’s Laboratories from manufacturing and exporting semaglutide (blockbuster weight loss and diabetes drug) to countries where it does not have a patent until its patent expires in March 2026. The appeal challenges a December 2 single judge decision that allowed Dr Reddy’s to continue exports while restricting domestic sales. The division bench will hear Novo’s appeal tomorrow, marking a sharp escalation in the legal battle ahead of the drug’s patent expiration in India.